Citigroup Inc G1 Therapeutics, Inc. Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in G1 Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 10,736 shares of GTHX stock, worth $76,762. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,736

Previous 129,066 91.68%

Holding current value

$76,762

Previous $557,000 95.69%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$2.2 - $4.98 $260,326 - $589,283	-118,330 Reduced 91.68%	10,736 $24,000
Q1 2024 May 10, 2024	BUY	$2.1 - $4.83 $90,545 - $208,255	43,117 Added 50.17%	129,066 $557,000
Q4 2023 Feb 09, 2024	BUY	$1.12 - $3.73 $95,542 - $318,191	85,306 Added 13266.87%	85,949 $262,000
Q3 2023 Nov 09, 2023	SELL	$1.22 - $2.67 $284 - $622	-233 Reduced 26.6%	643 $0
Q2 2023 Aug 10, 2023	SELL	$2.46 - $3.14 $1,916 - $2,446	-779 Reduced 47.07%	876 $2,000
Q1 2023 May 11, 2023	SELL	$2.57 - $8.16 $58,464 - $185,631	-22,749 Reduced 93.22%	1,655 $4,000
Q4 2022 Feb 09, 2023	SELL	$5.19 - $13.5 $534,076 - $1.39 Million	-102,905 Reduced 80.83%	24,404 $132,000
Q3 2022 Nov 10, 2022	BUY	$5.17 - $16.99 $651,921 - $2.14 Million	126,097 Added 10404.04%	127,309 $1.59 Million
Q2 2022 Aug 10, 2022	SELL	$4.04 - $8.51 $165,001 - $347,565	-40,842 Reduced 97.12%	1,212 $6,000
Q1 2022 May 12, 2022	SELL	$7.6 - $11.02 $1.71 Million - $2.48 Million	-225,119 Reduced 84.26%	42,054 $320,000
Q4 2021 Feb 10, 2022	BUY	$10.16 - $16.17 $1.32 Million - $2.1 Million	129,616 Added 94.23%	267,173 $2.73 Million
Q3 2021 Nov 10, 2021	BUY	$13.16 - $22.47 $1.81 Million - $3.09 Million	137,557 New	137,557 $1.85 Million

Others Institutions Holding GTHX

# of Institutions

101

Shares Held

20.1M

Call Options Held

1.87M

Put Options Held

1.18M

View Full List

About G1 Therapeutics, Inc.

Ticker GTHX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,746,800
Market Cap $306M
Description
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/...

More about GTHX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account